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Abstract
Rationale: In the absence of active tuberculosis, a positive tuberculin
skin test (TST) or interferon-g release assay (IGRA) result defines
latent infection withMycobacterium tuberculosis, although test
results may vary depending on immunodeficiency.
Objectives: This study compared the performance of TST and IGRAs
infive different groups of immunocompromised patients, and evaluated
their ability to identify those at risk for development of tuberculosis.
Methods: Immunocompromised patients with HIV infection,
chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell
transplantation, and healthy control subjects were evaluated head-to-
head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and
T-SPOT.TB test(enzyme-linkedimmunospot)at17centers in11European
countries. Development of tuberculosis was assessed during follow-up.
Measurements and Main Results: Frequencies of positive test
results varied from8.7 to 15.9% inHIV infection (n = 768), 25.3 to 30.6%
in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis
(n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197),
0% to5.8% in stem-cell transplant recipients (n = 103), and11.2 to15.2%
in immunocompetent control subjects (n = 211). Eleven patients (10
with HIV infection and one solid-organ transplant recipient) developed
tuberculosis during a median follow-up of 1.8 (interquartile range,
0.2–3.0) years. Six of the 11 patients had a negative or indeterminate test
result inall three testsat the timeof screening.Tuberculosis incidencewas
generally low, but higher inHIV-infected individualswith a positiveTST
(3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases
per 100 person-years) or enzyme-linked immunospot result (1.78 cases
per 100 person-years). No cases of tuberculosis occurred in patients who
received preventive chemotherapy.
Conclusions: Among immunocompromised patients evaluated in
this study, progression toward tuberculosis was highest in HIV-
infected individuals and was poorly predicted by TST or IGRAs.
Clinical trial registered with www.clinicaltrials.gov (NCT 00707317).
Keywords: interferon-g release assays; immunocompromised;
TBNET; tuberculin-skin test; tuberculosis
At a Glance Commentary
Scientific Knowledge on the Subject: Patients with
immunodeficiencies are particularly vulnerable to progression
from latent infection with Mycobacterium tuberculosis to
active disease. Tuberculin skin test and interferon-g release
assays are recommended for risk assessment for the future
development of tuberculosis, but knowledge of their
performance in immunocompromised patients is limited.
What This Study Adds to the Field: Tuberculin skin test and
interferon-g release assay responses vary substantially among
different groups of patients with immunodeficiencies and
are poor predictors for the development of tuberculosis in
immunocompromised patients.
Tuberculosis is a leading cause of morbidity
and mortality worldwide, and is the 10th
cause of all recorded deaths (1). In the
absence of an effective vaccine, tuberculosis
prevention relies on early case finding,
infection control measures, and preventive
chemotherapy of individuals latently
infected with Mycobacterium tuberculosis
(2). In clinical practice, latent infection with
M. tuberculosis (LTBI) is defined by the
presence of an adaptive immune response
against antigens of M. tuberculosis in
individuals without evidence of active
tuberculosis, and is either determined
in vivo by the tuberculin skin test (TST)
or ex vivo by interferon-g release assays
(IGRAs) (3). At present, two IGRAs are
commercially available: the QuantiFERON-
TB-Gold in-tube test (Qiagen, Hilden,
Germany), an ELISA; and the T-SPOT.TB
test (Oxford Immunotec, Abingdon, UK),
an enzyme-linked immunospot assay
(ELISPOT). A positive TST or IGRA result
is assumed to identify individuals with the
highest risk of progression to tuberculosis
(4). In most cases in patients from low-
incidence countries, tuberculosis is caused
by reactivation of LTBI, and could have
been avoided by preventive chemotherapy
following targeted TST or IGRA testing
(5). However, apart from individuals
from defined tuberculosis risk groups,
immunodiagnosis for LTBI and
preventive chemotherapy is not generally
recommended, because the positive
predictive value of the TST and IGRAs for
progression toward tuberculosis in the
general population is very low (4, 6),
especially in the absence of prior M.
tuberculosis exposure, and preventive
chemotherapy is not efficacious outside
of risk groups (7).
The risk for tuberculosis is directly
related to exposure with M. tuberculosis
and patients with immunodeficiencies are
particularly vulnerable to progression from
LTBI to active disease (8, 9). These include
HIV-infected individuals, transplant
recipients, patients with chronic renal
failure, or patients undergoing tumor
necrosis factor antagonist therapies.
In general, the risk for tuberculosis
in immunocompromised persons is
influenced by the underlying immunologic
mechanisms and degree of immunodeficiency,
and by the duration of and temporal
relationship with previous M. tuberculosis
exposure (8, 9). Because timing of
exposure outside of contact tracing
is generally unknown, a positive
immunodiagnostic test result is
considered as a proxy of prior
M. tuberculosis exposure. In addition, the
results of immunodiagnostic testing may
depend on the nature and extent of the
immunodeficiency and may not equally
predict the risk for tuberculosis among
different groups of immunocompromised
patients. Because a positive test in the
clinical setting is a finding on which
a clinician needs to act, increased
knowledge of performance and
limitations of the currently available
immunodiagnostic tests and their
ability to predict tuberculosis in
immunocompromised patients is needed.
In previous studies, the evaluation of
immunodiagnostic tests for LTBI was mostly
restricted to individual patients groups
(10–13) or individual assays (14–19). Our
study included five different groups of
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immunocompromised patients from 17
centers in 11 European countries, and tested
all three immunodiagnostic tests in parallel.
The two main objectives were to characterize
the performance of three immunodiagnostic
tests for LTBI in a patient population with
various etiologies of immunodeficiency, and
to assess the risk of developing tuberculosis in
patients with a positive immunodiagnostic
test at the time of screening.
Methods
Recruitment of Study Population
Study participants were recruited from 17
European healthcare facilities; 18 years of
age and older; and diagnosed with HIV
infection, chronic renal failure, rheumatoid
arthritis, solid-organ transplantation, or
stem-cell transplantation. All local ethics
committees approved the study and written
informed consent was obtained from
all individuals. Patients were recruited
from June 1, 2008 to May 31, 2011 in
a consecutive manner as part of their routine
care, and followed up for the development
of tuberculosis. We additionally included
adult control patients at the same facilities
from noninfectious disease departments
who did not have an immunocompromizing
clinical condition, and had a low risk for
M. tuberculosis exposure.
Study Design and Data Collection
The study included a cross-sectional part
where data on demographic and clinical
parameters, and data related to the risk of
M. tuberculosis exposure were obtained
through a structured questionnaire. In
addition, all participants had the three
separate tests for LTBI administered (3).
Experimental and clinical data were
recorded electronically and transmitted
to the coordinating center, where they
were assessed for inconsistencies or
missing entries. In the prospective part of
the study, follow-up information on the
occurrence of tuberculosis after initial
testing was actively sought and collected
by personal patient contact by the
treating physician.
Technical Procedures, Data Sources,
and Exposure Variables
The TST according to the Mantoux
technique (20) and the two IGRAs (the
ELISPOT, T-SPOT.TB; and the ELISA,
QuantiFERON-TB-Gold in-tube) were
performed as described in the online
supplement. The laboratory technicians
were fully masked to the M. tuberculosis
exposure status of the participants. The
TST could be performed a maximum of
30 days before the IGRAs.
M. tuberculosis exposure was defined
by a reported history of either exposure
to M. tuberculosis, active tuberculosis,
tuberculosis treatment, LTBI, or
chemoprophylaxis for LTBI, or being
a resident in a high tuberculosis incidence
country for at least 1 year. For stratified
analyses of subgroups, CD4 cell count was
dichotomized at 200 cells per microliter (21).
Duration of dialysis was dichotomized at
5 years, and the time after solid-organ
transplantation at 1 year. In addition, a drug
score was determined as specified in the
METHODS section of the online supplement to
quantify the level of immunosuppression
in transplant recipients. In patients with
rheumatoid arthritis, severity was classified
according to the disease activity score (DAS;
group I, ,3.3; group II, 3.3–5.1; group III,
.5.1) (22).
Statistical Analysis
The agreement between the proportions of
positive tests was assessed by Cochran-Q
test for matched samples (23). Agreement
between tests was assessed by the Kappa
statistics (24). The association between test
results and M. tuberculosis exposure was
assessed by logistic regression in which
confounding was deemed present if the
relationship between test result and
exposure changed by more than 10% after
inclusion of an exploratory variable. The
risk of tuberculosis by initial test results was
assessed using the Kaplan-Meier estimate in
survival analysis assessing patient follow-up
data at the earliest date of the last clinical
assessment, diagnosis of tuberculosis, death,
or end of follow-up (either 1, 2, or 5 yr after
testing). Only patients with at least 30 days
of follow-up were included in the analysis
to consider very early tuberculosis as
a screening failure rather than a valid case
of incident tuberculosis.
Results
Study Population
A total of 1,537 patients with
immunocompromizing medical conditions
(Figure 1) and 211 immunocompetent
control subjects were enrolled. Causes of
immunodeficiency included chronic HIV
infection (n = 768), chronic renal failure (n =
270), rheumatoid arthritis (n = 199), solid-
organ transplantation (n = 197; 134 renal, 41
lung, 17 liver, 4 renal-pancreas, and 1 renal-
liver transplants), and stem-cell transplantation
(n = 103) (Table 1). Information on the
distribution of patients by country is given in
Table E1 in the online supplement.
Cross-Sectional Study: Indeterminate
and Positive Test Results
TST, ELISA, and ELISPOT test results were
available from cross-sectional analysis
of 1,495 (97.3%), 1,532 (99.7%), and
1,503 (97.8%) patients, and 211 (100%),
208 (98.6%), and 209 (99.1%) control
subjects, respectively. The percentages of
patients
n=1537
TST
n=1495
positive
n=212
negative
n=1283
positive
n=239
negative
n=1184
indeterminate
n=109
positive
n=266
negative
n=1112
indeterminate
n=125
follow-up
n=196
follow-up
n=1208
follow-up
n=215
follow-up
n=1127
follow-up
n=99
follow-up
n=247
follow-up
n=1063
follow-up
n=112
TB
n=4
TB
n=7
TB
n=3
TB
n=5
TB
n=3
TB
n=4
TB
n=6
TB
n=1
42
missing
ELISA
n=1532
ELISPOT
n=1503
5
missing
34
missing
Figure 1. Flow chart of test results and cases of active tuberculosis (TB) in patients included in the
study. All patients with at least 30 days of follow-up were included to assess development of TB on
follow-up. ELISPOT = enzyme-linked immunospot assay; TB = tuberculosis; TST = tuberculin skin test.
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indeterminate and positive test results are
shown in Figures 2A and 2B, respectively.
The highest percentage of indeterminate
results in the ELISA was observed among
solid-organ and stem-cell transplant
recipients (Figure 2A; 20.3 and 20.4%,
respectively), whereas indeterminate results
in the ELISPOT assay were most frequently
observed in HIV-infected patients and
stem-cell transplant recipients (11.2
and 14.6%, respectively). Indeterminate
test results of IGRAs in these patient
groups were related to the extent of
immunosuppression (see Table E2). The
percentage of indeterminate results among
patients with chronic renal failure or
rheumatoid arthritis was only marginally
different from that observed in healthy
control subjects (Figure 2A). Overall, failure
to adequately react toward the positive
control stimulus was the cause of
indeterminate results in 85.0% of ELISA
and 50.4% of ELISPOT samples, whereas
excess reactivity in the negative control was
the reason for indeterminate results in
all other samples.
Percentages of positive test results
among all patients with valid results in all
three assays showed substantial differences
among the groups (Figure 2B). In general,
positive tests were most frequently observed
in patients with chronic renal failure
(25.3–30.6%) and rheumatoid arthritis
(25.0–37.2%), which contrasted with results
from HIV-infected patients and solid-organ
transplant recipients, respectively, where
only 8.7–15.9% and 9.0–20% of tests were
positive. The percentage of positive tests
in HIV-infected patients was lowest in
patients with low CD4 T-cell counts,
whereas the effect of the level of
immunodeficiency in other groups was less
evident (see Table E3). When comparing
the results of the three tests in each group,
the percentage of positive test results
among HIV-infected patients and solid-
organ transplant recipients was lower when
using the TST as compared with ELISA and
ELISPOT (P, 0.001 for HIV-infection;
P = 0.002 for solid-organ transplant
recipients). Among stem-cell transplant
recipients, positive tests were generally less
frequent and were only observed using the
IGRAs. The percentage of positive TST
results was significantly higher as compared
with that of IGRAs in patients with
rheumatoid arthritis (P = 0.003), whereas
no difference between the tests was found
in patients with chronic renal failure
(P = 0.121) (Figure 2B).
Cross-Sectional Study: Between-Test
Agreement and Association with
Exposure
When comparing results of the three
different tests, the agreement between the
two IGRAs was higher than that between
either IGRA and the TST (see Table E3).
Agreement between ELISA and ELISPOT
was substantial in patients with chronic
renal failure (K= 0.65) and rheumatoid
arthritis (K= 0.77), and moderate in
HIV-infected individuals (K= 0.50), and
solid-organ (K= 0.58) and stem-cell
transplant recipients (K= 0.41).
The association between self-reported
evidence of prior M. tuberculosis exposure
and test result was not confounded by age,
sex, or group-specific characteristics of
immunosuppression for any of the three
tests, with the exception of patients with
rheumatoid arthritis in which the DAS
score confounded this association (see
Table E4). Moderate associations of positive
IGRA results with exposure were found
in HIV-infected patients, which reached
statistical significance for the ELISPOT
(odds ratio [OR], 2.0; 95% confidence
interval [CI], 1.2–3.4), and near significance
for the ELISA (OR, 1.6; 95% CI, 0.9–3.1). In
patients after solid-organ transplantation,
Table 1. Demographic Characteristics of Patients and Control Subjects
HIV CRF RA SOT SCT
Control
Subjects
n = 768 n = 270 n = 199 n = 197 n = 103 n = 211
n % n % n % n % n % n %
Female 203 26.4 97 35.9 154 77.4 83 42.1 41 39.8 134 63.5
Age (median, IQR) 40.8 33.5–48.4 62.5 49.0–73.3 55.7 45.4–63.6 56.5 46.4–63.9 57.1 44.8–64.6 23.3 20.1–43.8
White 709 92.3 261 96.7 192 96.5 191 97.0 97 94.2 208 98.6
Immigrant 101 13.2 42 15.6 14 7.0 22 11.2 12 11.7 6 2.8
Years since immigration
(median, IQR)
9.0 3.0–16.0 22.5 11.5–38.5 20.0 8.0–30.0 38.5 26.0–42.0 33.0 21.5–40.5 27.0 23.0–32.0
Mycobacterium tuberculosis
exposure*
187 24.3 66 24.4 87 43.7 66 33.5 24 23.3 0 0.0
History of exposure to
M. tuberculosis
44 5.7 28 10.4 19 9.6 31 15.7 3 2.9 0 0.0
History of active TB 62 8.1 19 7.0 9 4.5 11 5.6 2 1.9 0 0.0
History of TB treatment 58 7.6 13 4.8 6 3.0 6 3.1 1 1.0 0 0.0
History of LTBI 13 1.7 1 0.4 20 10.1 31 15.7 0 0.0 0 0.0
History of LTBI
chemoprophylaxis
8 1.0 1 0.4 14 7.0 6 3.1 18 17.5 0 0.0
.1 yr in high TB–incidence
country
94 12.2 28 10.4 55 27.6 10 5.1 3 2.9 0 0.0
Valid results in all three tests† 635 82.4 245 90.7 164 82.4 145 73.6 69 67.0 197 93.4
Definition of abbreviations: CRF = chronic renal failure; HIV = HIV-infected patients; IQR = interquartile range; LTBI = latent infection with M. tuberculosis;
RA = rheumatoid arthritis; SCT = stem-cell transplantation; SOT = solid-organ transplantation; TB = tuberculosis.
*Self-reported evidence of prior “M. tuberculosis exposure” defined by a reported history of either exposure to M. tuberculosis, active tuberculosis,
tuberculosis treatment, LTBI or chemoprophylaxis for LTBI, or being at least for 1 year a resident in a high TB–incidence country; immigrants were only
included in the “M. tuberculosis exposure group” if patients had lived in high TB–prevalence countries for more than 1 year before immigration.
†Valid results include positive and negative tests and exclude indeterminates.
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a positive ELISA was significantly
associated with exposure (OR, 2.2; 95% CI,
1.0–4.6). A significant association of each of
the three tests with exposure existed for
patients with rheumatoid arthritis. After
adjusting for DAS score, the OR was 2.7
(95% CI, 1.4–5.1) for TST, 4.4 (95% CI,
2.1–9.4) for ELISA, and 4.9 (95% CI,
2.4–10.2) for ELISPOT. Conversely,
although the percentage of positive test
results in patients with chronic renal failure
and rheumatoid arthritis was similarly high
(Figure 2B), a positive TST or IGRA in
patients with chronic renal failure was
not associated with evidence of prior
M. tuberculosis exposure.
When analyzing the number of positive
tests in the three assays in relation to
exposure status, the percentage of cases
with three negative tests decreased along
a gradient of likely exposure, and was
highest in individuals nonexposed to
M. tuberculosis (see Table E5). Likewise,
the percentage of individuals with three
positive tests increased with increasing
exposure and ranged from 4.9% in
nonexposed to 13.4% in cases where
exposure was likely highest. Of note, this
also held true for cases where only the two
IGRAs were positive. In contrast, the
percentage of individuals with only one
positive test was rather similar across the
groups (see Table E5).
Prospective Study: Incidence of
Tuberculosis
Of the 1,537 patients, a total of 1,464
(95.3%) had an assessment of tuberculosis
on follow-up and were included in the
prospective part of the study. Eighteen
patients were excluded because of a follow-
up of less than 30 days. The number of
patients with either a positive or negative
test result included in the analysis for
tuberculosis incidence was 1,404 for the
TST, 1,342 for the ELISA, and 1,310 for the
ELISPOT. A total of 11 patients developed
active tuberculosis in the median follow-up
time of 1.8 years (interquartile range [IQR],
0.2–3.0). Of these, 10 patients were
HIV-infected and one was a solid-organ
transplant recipient (Table 2). No cases of
tuberculosis were observed among patients
with chronic renal failure, rheumatoid
arthritis, stem-cell transplantation, or
control subjects. All patients who developed
tuberculosis were born in a medium- or
high-prevalence country for tuberculosis
and had not received preventive
chemotherapy after testing. Among HIV-
infected patients, viral load was detectable
in all cases (median, 20,593 copies per
microliter; IQR, 82.5–49,819 copies per
microliter), and median CD4 T-cell counts
were 302 per microliter (IQR, 196–370
per microliter) (Table 2). Six out of the
11 patients either had a negative or
indeterminate test result at the time of
testing and only two had positive test
results in all three assays (Table 2).
The incidence of tuberculosis in
HIV-infected patients with a positive test was
generally higher as compared with a negative
test (see Table E6). Two years after testing,
the incidence was higher in patients with
a positive TST result (3.26 cases per 100
person-years) as compared with the ELISPOT
(1.80 per 100 person-years) and the ELISA
(1.37 per 100 person-years) (see Table E6).
Similar results were obtained after 1 and
5 years of follow-up (see Table E6).
Finally, the influence of preventive
chemotherapy administered after testing on
progression to tuberculosis was analyzed for
all patients after 1, 2, and 5 years (Table 3).
Information on preventive chemotherapy
by patient group and country is given in
Table E1. Among patients, 21.3% (47 of
196) of TST positives, 26.0% (56 of 215)
of ELISA positives, and 24.0% (54 of 247)
of ELISPOT positives received preventive
chemotherapy. No case of tuberculosis
occurred in these individuals. Among
patients who had not received preventive
chemotherapy, the incidence of tuberculosis
in individuals with a negative test was
expectedly low (0.15, 0.11, and 0.17 per 100
person-years after 2 yr for TST, ELISA, and
ELISPOT, respectively). In contrast, the
incidence of tuberculosis after a positive TST,
ELISA, or ELISPOT was 1.15, 0.71, and
0.88 per 100 person-years after 2 years,
respectively. Similar results were obtained
after 1 and 5 years of follow-up (Table 3).
Taken together, although the incidence of
tuberculosis was higher in patients with
positive test results, IGRAs were not superior
in identifying patients at risk for developing
tuberculosis when compared with the TST.
Discussion
We have evaluated currently available
immunodiagnostic tests for the
identification of LTBI and their value in
controls
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Figure 2. Results of immune-based testing in immunocompromised patients and control subjects.
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(ELISPOT) assay and (B) the percentage of positive test results among patients with valid results in all
three tests was quantified. CRF = chronic renal failure; RA = rheumatoid arthritis; SCT = stem-cell
transplantation; SOT = solid-organ transplantation; TST = tuberculin skin test.
ORIGINAL ARTICLE
1172 American Journal of Respiratory and Critical Care Medicine Volume 190 Number 10 | November 15 2014
T
ab
le
2.
C
ha
ra
ct
er
is
tic
s
of
P
at
ie
nt
s
D
ev
el
op
in
g
A
ct
iv
e
Tu
b
er
cu
lo
si
s
on
Fo
llo
w
-u
p
C
o
un
tr
y
o
f
B
ir
th
/A
ct
ua
l
R
es
id
en
ce
S
ex
T
B
(m
o
af
te
r
T
es
ti
n
g
)
T
B
T
yp
e
T
B
D
ia
g
no
si
s
T
S
T
(m
m
)
E
LI
S
P
O
T
(S
FC
)
E
LI
S
A
(U
/m
l)
C
he
m
o
p
re
ve
nt
io
n
H
IV
C
D
C
H
A
A
R
T
H
IV
Lo
ad
C
D
4
T
C
el
ls
/m
l
O
ff
er
ed
D
o
ne
H
IV
A
rg
en
tin
a/
Ita
ly
M
al
e
1.
1
P
ul
m
on
ar
y
C
lin
ic
al
*
P
os
iti
ve
(2
0)
P
os
iti
ve
(1
8)
P
os
iti
ve
(2
.7
)
N
o
N
o
C
2
N
o
25
,2
85
49
2
H
IV
B
ul
ga
ria
/B
ul
ga
ria
M
al
e
1.
3
E
xt
ra
p
ul
m
on
ar
y
C
ul
tu
re
co
nfi
rm
ed
P
os
iti
ve
(1
2)
P
os
iti
ve
(1
6)
P
os
iti
ve
(0
.3
9)
N
o
N
o
C
3
Y
es
83
,1
76
24
5
H
IV
P
or
tu
ga
l/P
or
tu
ga
l
M
al
e
2.
0
P
ul
m
on
ar
y
C
ul
tu
re
co
nfi
rm
ed
P
os
iti
ve
(5
)
P
os
iti
ve
(1
25
)
N
eg
at
iv
e
(0
.1
5)
Y
es
N
o
A
3
N
o
38
,7
00
22
H
IV
P
or
tu
ga
l/P
or
tu
ga
l
Fe
m
al
e
2.
5
P
ul
m
on
ar
y
C
lin
ic
al
*
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(0
)
N
o
N
o
A
2
N
o
15
,9
00
37
1
H
IV
P
or
tu
ga
l/P
or
tu
ga
l
M
al
e
8.
4
B
ot
h
C
ul
tu
re
co
nfi
rm
ed
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(1
)
In
d
et
er
m
in
at
e
(0
.1
3)
Y
es
N
o
C
3
Y
es
12
0,
00
0
50
H
IV
P
or
tu
ga
l/P
or
tu
ga
l
Fe
m
al
e
21
.8
B
ot
h
C
ul
tu
re
co
nfi
rm
ed
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(4
)
In
d
et
er
m
in
at
e
(0
)
Y
es
N
o
A
1
N
o
38
,2
00
33
3
S
O
T
C
ro
at
ia
/G
er
m
an
y
Fe
m
al
e
25
.2
E
xt
ra
p
ul
m
on
ar
y
P
C
R
co
nfi
rm
ed
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(0
)
In
d
et
er
m
in
at
e
(0
)
N
o
N
o
N
A
N
A
N
A
U
nk
no
w
n
H
IV
P
or
tu
ga
l/P
or
tu
ga
l
M
al
e
33
.6
B
ot
h
C
ul
tu
re
co
nfi
rm
ed
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(1
)
N
eg
at
iv
e
(0
.0
9)
N
o
N
o
A
2
N
o
,
50
36
9
H
IV
E
rit
re
a/
G
er
m
an
y
M
al
e
35
.4
P
ul
m
on
ar
y
C
lin
ic
al
*
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(0
)
N
eg
at
iv
e
(0
.1
2)
N
o
N
o
C
3
Y
es
60
27
1
H
IV
A
rg
en
tin
a/
Ita
ly
M
al
e
52
.5
P
ul
m
on
ar
y
C
ul
tu
re
co
nfi
rm
ed
P
os
iti
ve
(1
0)
In
d
et
er
m
in
at
e
(4
9)
†
P
os
iti
ve
(0
.7
)
N
o
N
o
A
2
N
o
10
,0
71
26
3
H
IV
E
rit
re
a/
G
er
m
an
y
M
al
e
56
.7
P
ul
m
on
ar
y
C
ul
tu
re
co
nfi
rm
ed
N
eg
at
iv
e
(0
)
P
os
iti
ve
(9
)
N
eg
at
iv
e
(0
.0
9)
N
o
N
o
A
3
Y
es
90
35
4
D
e
fin
iti
o
n
o
f
a
b
b
re
vi
a
tio
n
s:
E
L
IS
P
O
T
=
e
n
zy
m
e
-l
in
ke
d
im
m
u
n
o
sp
o
t
a
ss
a
y;
H
A
A
R
T
=
h
ig
h
ly
a
c
tiv
e
a
n
tir
e
tr
o
vi
ra
lt
h
e
ra
p
y;
P
C
R
=
p
o
ly
m
e
ra
se
c
h
a
in
re
a
c
tio
n
;
S
F
C
=
sp
o
t
fo
rm
in
g
c
e
lls
;
S
O
T
=
so
lid
-o
rg
a
n
tr
a
n
sp
la
n
ta
tio
n
;
T
B
=
tu
b
e
rc
u
lo
si
s;
T
S
T
=
tu
b
e
rc
u
lin
sk
in
te
st
.
“H
IV
C
D
C
”
re
fe
rs
to
th
e
c
la
ss
ifi
c
a
tio
n
b
y
th
e
U
n
ite
d
S
ta
te
s
C
e
n
te
rs
fo
r
D
is
e
a
se
C
o
n
tr
o
l
a
n
d
P
re
ve
n
tio
n
(C
D
C
).
*T
h
e
d
ia
g
n
o
si
s
o
f
c
lin
ic
a
l
tu
b
e
rc
u
lo
si
s
w
a
s
b
a
se
d
o
n
si
g
n
s
a
n
d
sy
m
p
to
m
s
o
f
a
c
tiv
e
tu
b
e
rc
u
lo
si
s
a
n
d
re
sp
o
n
se
to
a
n
tit
u
b
e
rc
u
lo
si
s
th
e
ra
p
y.
†
In
d
e
te
rm
in
a
te
b
e
c
a
u
se
o
f
2
2
S
F
C
in
th
e
N
il
c
o
n
tr
o
l.
T
ab
le
3.
Fo
llo
w
-u
p
fo
r
A
ct
iv
e
Tu
b
er
cu
lo
si
s
D
ep
en
d
in
g
on
Te
st
R
es
ul
t
an
d
P
ro
p
hy
la
xi
s
1,
2,
an
d
5
Y
ea
rs
af
te
r
Te
st
in
g
fo
r
La
te
nt
In
fe
ct
io
n
w
ith
M
yc
ob
ac
te
riu
m
tu
b
er
cu
lo
si
s
T
es
t
R
es
ul
t*
P
ro
p
hy
la
xi
s†
N
1
yr
2
yr
5
yr
P
Y
at
R
is
k
T
B
C
as
es
In
ci
d
en
ce
‡
P
Y
at
R
is
k
T
B
C
as
es
In
ci
d
en
ce
‡
P
Y
at
R
is
k
T
B
C
as
es
In
ci
d
en
ce
‡
TS
T
N
eg
at
iv
e
N
o
1,
13
3
10
84
.2
2
0.
18
(0
.0
5–
0.
74
)
19
51
.5
3
0.
15
(0
.0
5–
0.
48
)
30
76
.4
7
0.
23
(0
.1
1–
0.
48
)
N
eg
at
iv
e
Y
es
75
73
.0
0
0
11
0.
1
0
0
13
1.
2
0
0
P
os
iti
ve
N
o
14
9
14
4.
5
3
2.
08
(0
.6
7–
6.
44
)
26
1.
5
3
1.
15
(0
.3
7–
3.
56
)
38
2.
4
4
1.
05
(0
.3
9–
2.
79
)
P
os
iti
ve
Y
es
47
46
.7
0
0
82
.8
0
0
10
5.
0
0
0
E
LI
S
A
N
eg
at
iv
e
N
o
1,
07
9
10
36
.6
2
0.
19
(0
.0
5–
0.
77
)
18
64
.4
2
0.
11
(0
.0
3–
0.
44
)
28
95
.2
5
0.
17
(0
.0
7–
0.
41
)
N
eg
at
iv
e
Y
es
48
46
.6
0
0
77
.8
0
0
95
.1
0
0
P
os
iti
ve
N
o
15
9
15
1.
8
2
1.
32
(0
.3
3–
5.
27
)
28
2.
4
2
0.
71
(0
.1
8–
2.
83
)
46
2.
4
3
0.
65
(0
.2
1–
2.
01
)
P
os
iti
ve
Y
es
56
55
.4
0
0
85
.6
0
0
10
0.
5
0
0
E
LI
S
P
O
T
N
eg
at
iv
e
N
o
1,
02
4
97
6.
2
2
0.
20
(0
.0
5–
0.
82
)
17
52
.8
3
0.
17
(0
.0
6–
0.
53
)
27
18
.3
6
0.
22
(0
.1
0–
0.
49
)
N
eg
at
iv
e
Y
es
39
37
.3
0
0
64
.2
0
0
84
.7
0
0
P
os
iti
ve
N
o
19
3
18
3.
3
3
1.
64
(0
.5
3–
5.
07
)
34
2.
0
3
0.
88
(0
.2
8–
2.
72
)
55
6.
7
4
0.
72
(0
.2
7–
1.
91
)
P
os
iti
ve
Y
es
54
53
.9
0
0
86
.3
0
0
10
3.
7
0
0
D
e
fin
iti
o
n
o
f
a
b
b
re
vi
a
tio
n
s:
E
L
IS
P
O
T
=
e
n
zy
m
e
-l
in
ke
d
im
m
u
n
o
sp
o
t
a
ss
a
y;
P
Y
=
p
e
rs
o
n
-y
e
a
r;
T
B
=
tu
b
e
rc
u
lo
si
s;
T
S
T
=
tu
b
e
rc
u
lin
sk
in
te
st
.
*T
h
is
a
n
a
ly
si
s
in
c
lu
d
e
s
a
ll
p
a
tie
n
ts
w
ith
va
lid
te
st
re
su
lts
(p
o
si
tiv
e
o
r
n
e
g
a
tiv
e
),
w
h
e
re
a
s
in
d
e
te
rm
in
a
te
te
st
re
su
lts
w
e
re
n
o
t
c
o
n
si
d
e
re
d
in
th
is
a
n
a
ly
si
s.
†
P
ro
p
h
yl
a
xi
s
re
fe
rs
to
tr
e
a
tm
e
n
t
a
d
m
in
is
te
re
d
a
ft
e
r
th
e
T
S
T
/i
n
te
rf
e
ro
n
-g
re
le
a
se
a
ss
a
ys
te
st
p
e
rf
o
rm
e
d
in
th
is
st
u
d
y.
‡
In
c
id
e
n
c
e
is
g
iv
e
n
p
e
r
1
0
0
P
Y
;
th
e
ra
te
s
re
fe
r
to
th
e
c
u
m
u
la
tiv
e
ra
te
s
a
ft
e
r
1
,
2
,
a
n
d
5
ye
a
rs
a
ft
e
r
te
st
in
g
fo
r
la
te
n
t
in
fe
c
tio
n
w
ith
M
.
tu
b
e
rc
u
lo
si
s.
ORIGINAL ARTICLE
Sester, van Leth, Bruchfeld, et al.: IGRAs in Immunocompromised Patients 1173
assessing the risk for progression to
active tuberculosis in a large cohort of
patients with different etiologies of
immunodeficiencies in Europe. As most
important findings we identified substantial
differences in the frequencies of positive
M. tuberculosis–specific immune responses
among patients with HIV infection,
rheumatoid arthritis, chronic renal failure,
and solid-organ or stem-cell transplants,
whereas less prominent variations
were observed between the TST, the
QuantiFERON-TB-Gold in-tube, and the
T-SPOT.TB test within these groups.
Of note, among immunocompromised
patients, the risk for the development
of tuberculosis was clearly highest in
HIV-infected individuals.
The strength of this large
prospective cohort study is that all three
immunodiagnostic tests were evaluated in
parallel in patients from five groups of
different etiologies of immunodeficiencies,
which allowed for a direct comparison of
results within one study. Unlike skin
testing, IGRAs are less influenced by
immunosuppression in HIV-infected
individuals and in patients after solid-organ
or stem-cell transplantation. Similarities
in test performance in these two patient
groups may result from the fact that both
immunodeficiencies primarily affect T cells,
and lower percentages of positive test results
appear to be caused by either an HIV-related
overall decrease in CD4 T-cell counts (11,
25, 26) or by a drug-induced inhibition of
T-cell functionality (27). In contrast, higher
percentages of positive test results were
found in patients with chronic renal
failure or rheumatoid arthritis where
immunodeficiency is multifactorial and not
primarily acting on T cells (28). Patients
with rheumatoid arthritis were striking in
that the highest percentage of positive test
results were found with the TST. However,
because between-test agreement was
higher among IGRAs, and both IGRAs
showed a strong association with prior
M. tuberculosis exposure, the TST seems
to be less specific and seems to measure
different subpopulations of patients.
The proportion of indeterminate
IGRA results was expectedly lowest in
immunocompetent control subjects,
whereas up to 20% of indeterminate
results were found in patients. Subgroup
analyses indicated that a higher percentage
was associated with markers of
immunodeficiency, such as CD4 T-cell
counts less than 200 cells per microliter, or
recent transplantation attendant with higher
levels of immunosuppression with multiple
drugs in solid-organ and stem-cell
transplant recipients. The findings in HIV-
infected patients are in line with previous
reports suggesting that HIV-positive
individuals with less than 200 CD41
T cells per microliter have impaired
IGRA response (10, 11, 17, 18, 26). The
proportion of indeterminate results in this
study was lowest among patients with
rheumatoid arthritis and renal failure,
which was generally in line with
indeterminate result rates in other studies
in these patient groups (12, 29–34).
Together with the highest percentage of
positive test results, this suggests that
immunodiagnostic assays in these two
patient groups are least affected by the
underlying etiology of immunodeficiency.
Tuberculosis incidence rates found
after positive tests are in line with estimates
from systematic reviews of predictive value
of IGRAs for incident active tuberculosis,
which have predominantly included
nonimmunocompromised individuals
during contact tracing (6, 35). Up to
now, only a few studies exist that have
specifically analyzed progression in
immunocompromised patients, and most
studies have only used one IGRA without
comparison with TST (36). Most studies
did not report incidence rates, but the
percentage of tuberculosis cases among
untreated patients with positive IGRA
results ranged from 7 to 20% in HIV-
infected patients (17, 19, 37), 5.6% in
patients after renal transplantation (15),
and 2.6% in patients before tumor necrosis
factor antagonist therapy of which only
a small number had rheumatoid arthritis
(38). In our multicenter European study,
incident cases of tuberculosis were lower
and were almost exclusively found among
HIV-infected patients. Most of these
patients did not receive antiretroviral
therapy and those who did still had
detectable levels of viral replication
confirming that antiretroviral therapy alone
reduces the risk for the development of
tuberculosis in HIV-infected patients
substantially (39, 40). Although positive test
results were generally more frequently
observed with IGRAs as compared with
the TST, progression to tuberculosis also
occurred in patients with a negative result
in any of the three tests. In half of the
tuberculosis cases, LTBI was not detectable
by any of the tests at the time of screening
and positive results in all three tests
were only observed in 2 of 11 patients
who subsequently developed tuberculosis.
Results from the current study further
show that a higher percentage of positive
test results in a given group of
immunocompromised patients does not
indicate a substantially higher risk for
progression to tuberculosis. This is
illustrated by the fact that no cases of
active tuberculosis were observed
among patients with renal failure or
patients with rheumatoid arthritis not
receiving preventive chemotherapy,
although these were the patient groups
with the highest percentage of positive
test results. In contrast, the risk of
developing tuberculosis was highest for
patients with HIV infection, although the
frequency of positive test results was
substantially lower. These findings indicate
that in immunocompromised patients,
none of the three tests is sufficient
to assess the risk of progression to
tuberculosis.
A recent study in military recruits
indicated that individuals where all
three tests were positive had a higher
epidemiologic risk of prior infection,
whereas individuals with only one positive
test were suggested to be likely false-positive
(41). In line with these findings, the
percentage of individuals with positive
test results in all three assays or with two
positive IGRAs in our study was also
highest in cases with highest likelihood of
exposure. The fact that the percentage of
patients where only one test was positive
was less strikingly associated with exposure
variables may be considered as a hint
toward false-positive results, but this may
also be influenced by variable effects of
immunodeficiency on immune reactivity
in vivo and in vitro.
It is unclear which test should be
preferred for immunodiagnostic testing.
When cross-sectionally comparing test
results obtained by IGRAs and TST, IGRAs
generally had a higher rate of positivity and
were more strongly associated with
M. tuberculosis exposure. However, results
from the longitudinal part of this study may
suggest superiority of the TST for risk
assessment in HIV-infected patients.
However, given the considerably high
percentage of positive tests and the low
number of tuberculosis cases on follow-up,
there was no striking difference between
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the tests and neither IGRA nor TST was
adequately able to predict those at risk. In
addition, although progression rates were
low in patients with negative test results,
physicians caring for immunocompromised
patients must be aware that a negative
result with any of the currently available
tests does not rule out the future risk of
developing tuberculosis.
The results from this study should have
implications for refining future screening
policies in immunocompromised patients in
countries with low tuberculosis incidence.
The low progression rates among test-
positive individuals emphasize the
limitations of current recommendations
(7, 42) to screen all patients with chronic
renal failure or with rheumatoid arthritis
for LTBI in the absence of additional risk
factors for tuberculosis. Because at least
50% of HIV-infected patients who
developed tuberculosis had negative test
results at the time of screening, both the
positive and negative predictive values of
any of the immunodiagnostic tests were
very poor in low-incidence countries.
Because development of tuberculosis was
almost exclusively observed in patients with
ongoing HIV replication, the data are
consistent with lower tuberculosis rates
associated with effective antiretroviral
therapy, and it may be suggested that
HIV-infected patients with positive
immunodiagnostic test results do not
have an increased risk of developing
tuberculosis when HIV-replication
is suppressed to undetectable levels by
antiretroviral therapy. This emphasizes
that the effect of antiretroviral therapy
needs to be carefully studied and addressed
when future policies for tuberculosis
prevention are made for HIV-infected
patients in countries of low tuberculosis
prevalence.
The study has some limitations,
of which most are inherent to the
nonrandomized observational study design.
The low number of cases with tuberculosis
may be confounded by the fact that patients
with the highest presumed risk for
the development of tuberculosis were
potentially more likely to have received
preventive chemotherapy. Although formal
randomization of receiving preventive
therapy is ethically questionable, techniques
to adjust for this treatment-by-indication
bias, such as inverse probability weighting
(43), could not be reliably used given the
small proportion of patients receiving
preventive therapy and the limited
information of confounding variables. In
addition, as in the setting of contact tracing,
comparisons of progression rates toward
tuberculosis among different groups of
immunocompromised patients would be
least biased if patients were harmonized for
presumptive exposure, and if exogenous
reinfection rates were either absent or
identical. However, in this observational
study, the time of exposure is largely
unknown, which is caused by the fact that
risk assessment in immunocompromised
patients in a clinical routine setting is
not primarily guided by recent contact.
One of Comstocks studies in military
recruits showed a high predictive value of
a positive TST in the first year, whereas
rates were increasing over 5 years of
follow-up in those with baseline negative
tests (44). In our study, we did not perform
serial testing or specifically collect
information on reexposure after testing.
Therefore, we could not exclude that
infection with M. tuberculosis occurred
after screening, although incidence
rates for tuberculosis were similar in
individuals with HIV infection at the
different time points of follow-up. Finally,
this study was not powered to identify
regional differences in the role of
different assays to assess development
of tuberculosis.
In conclusion, the performance of TST
and IGRAs differs among patients with
various etiologies of immunodeficiency.
Immunocompromised patients at risk for
developing tuberculosis are poorly identified
by both TST and IGRAs. Better methods
and biomarkers are urgently needed to
specifically target preventive chemotherapy
in immunocompromised individuals who
would otherwise develop tuberculosis in
the future. n
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